Cutia Therapeutics Relative Valuation - Cutia Therapeutics - Alpha Spread
C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 14.06 HKD -0.28% Market Closed
Market Cap: 4.3B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

Relative Value

The Relative Value of one Cutia Therapeutics stock under the Base Case scenario is 16.95 HKD. Compared to the current market price of 14.06 HKD, Cutia Therapeutics is Undervalued by 17%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
16.95 HKD
Undervaluation 17%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
5
vs Industry
37
Median 3Y
10
Median 5Y
10
Industry
7.7
Forward
13.9
vs History
vs Industry
Median 3Y
-6.8
Median 5Y
-6.8
Industry
23.9
Forward
-8.2
vs History
vs Industry
Median 3Y
-8
Median 5Y
-8
Industry
22.2
vs History
vs Industry
Median 3Y
-11.6
Median 5Y
-11.6
Industry
24
vs History
35
vs Industry
50
Median 3Y
2.3
Median 5Y
2.3
Industry
2.5
vs History
0
vs Industry
44
Median 3Y
5.1
Median 5Y
5.1
Industry
7.4
Forward
10.5
vs History
0
vs Industry
29
Median 3Y
10.2
Median 5Y
10.2
Industry
8.5
vs History
vs Industry
Median 3Y
-0.5
Median 5Y
-0.5
Industry
5.1
Forward
-6.4
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-4.9
Industry
4.7
Forward
-6
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-5.1
Industry
6.6
vs History
vs Industry
Median 3Y
-4.5
Median 5Y
-4.5
Industry
4.7
vs History
0
vs Industry
37
Median 3Y
4.4
Median 5Y
4.4
Industry
4.7

Multiples Across Competitors

Competitors Multiples
Cutia Therapeutics Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Cutia Therapeutics
HKEX:2487
4.3B HKD 19.5 -7.4 -6 -5.6
US
Abbvie Inc
NYSE:ABBV
341.5B USD 6.2 64.5 15.7 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
129B USD 9.6 29.8 26.2 29
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.6B USD 12 -252.2 26.8 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
105B USD 3.8 99.7 9.5 12
US
Epizyme Inc
F:EPE
94.1B EUR 1 975 -504 -548.8 -534.2
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.4 22.3 27.8
US
Seagen Inc
F:SGT
39.3B EUR 19 -58.3 -62.8 -56.7
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.2B USD 15 -483 212.6 327.3
P/E Multiple
Earnings Growth
CN
C
Cutia Therapeutics
HKEX:2487
Average P/E: 57.6
Negative Multiple: -7.4
N/A
US
Abbvie Inc
NYSE:ABBV
64.5
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.8
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.7
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -504 N/A
AU
CSL Ltd
ASX:CSL
36.4
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.3 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -483 N/A
EV/EBITDA Multiple
EBITDA Growth
CN
C
Cutia Therapeutics
HKEX:2487
Average EV/EBITDA: 47.6
Negative Multiple: -6
N/A
US
Abbvie Inc
NYSE:ABBV
15.7
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.2
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
Gilead Sciences Inc
NASDAQ:GILD
9.5
10%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -548.8 N/A
AU
CSL Ltd
ASX:CSL
22.3
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -62.8 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
212.6
N/A
EV/EBIT Multiple
EBIT Growth
CN
C
Cutia Therapeutics
HKEX:2487
Average EV/EBIT: 69.3
Negative Multiple: -5.6
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.6
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.2 N/A
AU
CSL Ltd
ASX:CSL
27.8
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.7 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
327.3
N/A

See Also

Discover More
Back to Top